Icelandic Research Data Contributes to Landmark Fibromyalgia Genetics Study
In a landmark study published in Nature Medicine (https://www.nature.com/articles/s41591-026-04492-6), an international team of researchers have identified new genetic risk factors associated with fibromyalgia suggesting that the biological basis of the condition is...
AMGEN DECODE GENETICS ANNOUNCES APPOINTMENT OF DANÍEL F. GUDBJARTSSON AS SITE HEAD
deCODE genetics, a subsidiary of the global biotechnology company Amgen, today announced the appointment of Daníel F. Guðbjartsson, Ph.D. as Associate Vice President and Site Head. In this role, Dr. Guðbjartsson will lead site operations for deCODE genetics, further...
CEO of Amgen visited Amgen deCODE in Reykjavik
Bob Bradway with the leadership team of Amgen deCODE genetics. Bob Bradway, CEO of Amgen, visited the facilities of Amgen deCODE genetics (ADG) on Wednesday, March 11. During the visit he learned about the company’s operations, met with executives and...
Genetic Risk Signal in Lupus Identified Through a Distinctive Dataset
In a paper published in Nature Genetics, researchers at Amgen deCODE genetics and collaborators report an important insight into the genetics of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) : a rare variant in the gene IKBKB (encoding the...
UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.